ANI Pharmaceuticals Q1 2026 Earnings Strong EPS Beat Highlights Operational Strength RRX Q1 2026 Earnings Earnings Beat on Solid Execution Amid Mixed Market Conditions GLMD Q4 2025 Earnings WiderThanExpected Loss as Galmed Continues Clinical Development CSAN Q1 2026 Earnings Heavy Losses as EPS Misses Estimates by a Wide Margin ALTO Q1 2026 Earnings Strong Profitability Surprises Markets MPU Q3 2023 Earnings Reported Net Loss per Share of 005 Amidst Stock Decline